Overall, current data advocate CRC patient stratification by determining the tumor’s MMR status, either by testing for MSI or immunohistochemical analysis of MMR proteins, in order to decide on adjuvant chemotherapy on an individual basis. This evidence concerns the gene MRC1 and neoplasm.